ArticleMovement disorders clinical practice2025

Reply: "Navigating the Neuropsychiatric Risks of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease".

Fabien Hauw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.